NIBAN2 Stimulates Glioma Growth by Regulating the JAK2/STAT3/c‐Myc Pathway
Cancer Medicine · 2025
DOI: 10.1002/cam4.71239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Zhi-Ming Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Janus Kinase 2, STAT3 Transcription Factor, Glioma, Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program, Ministry of Science and Technology of China, Research Grant of the Clinical Medical Research Center for Central Nervous System Repair and Functional Reconstruction of Hubei Province.
Abstract (Originalsprache)
Background
Niban‐like protein 2 (NIBAN2) has recently been linked to various neurological diseases; however, its exact role in glioma development remains unclear.
Methods
Quantitative reverse transcription–polymerase chain reaction, western blotting, and immunohistochemistry were used to evaluate NIBAN2 expression in glioma tissues. In addition, we examined the effects of NIBAN2 on glioma progression in various functional trials. Animal models were used to clarify the role of NIBAN2, especially its impact on the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway.
Results
The research outcomes revealed that NIBAN2 was highly upregulated in gliomas and its levels were strongly correlated with tumor grade and clinical outcomes. Functional assays showed that NIBAN2 enhanced glioma cell aggressiveness by activating JAK2/STAT3 signaling and promoted tumor growth by preventing apoptosis and accelerating the cell cycle.
Conclusion
The findings of this study show that NIBAN2 plays a key role in glioma aggression and poor prognosis, suggesting that it is a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, Beijing, China.
- Department of Neurosurgery, Hubei Provincial Clinical Research Center of Central Nervous System Repair and Functional Reconstruction, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
- Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
- Department of Obstetrics, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei, People's Republic of China.
ORCID-Profile: Jun Liu, Chang-Xiang Yan
Förderung
- Key Research and Development Program, Ministry of Science and Technology of China
- Research Grant of the Clinical Medical Research Center for Central Nervous System Repair and Functional Reconstruction of Hubei Province
Zitieren
APA
Chen, Z. M., Mou, L., Pan, Y. H., Feng, C., Liu, J., Zhang, J. J., & Yan, C. X. (2025). NIBAN2 Stimulates Glioma Growth by Regulating the JAK2/STAT3/c‐Myc Pathway. Cancer Medicine. https://doi.org/10.1002/cam4.71239
Vancouver
Chen ZM, Mou L, Pan YH, Feng C, Liu J, Zhang JJ, et al. NIBAN2 Stimulates Glioma Growth by Regulating the JAK2/STAT3/c‐Myc Pathway. Cancer Medicine. 2025. doi:10.1002/cam4.71239
BibTeX
@article{Chen2025,
author = {Chen, Zhi-Ming and Mou, Lei and Pan, Yi-Heng and Feng, Chi and Liu, Jun and Zhang, Jing-Jing and Yan, Chang-Xiang},
title = {NIBAN2 Stimulates Glioma Growth by Regulating the JAK2/STAT3/c‐Myc Pathway},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71239}
}
EUVIMED